1. Home
  2. BBNX vs CCCC Comparison

BBNX vs CCCC Comparison

Compare BBNX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$14.61

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.87

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
CCCC
Founded
2015
2015
Country
United States
United States
Employees
423
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
404.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BBNX
CCCC
Price
$14.61
$3.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
6
Target Price
$23.80
$12.20
AVG Volume (30 Days)
780.1K
2.9M
Earning Date
04-21-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
$34.90
N/A
Revenue Next Year
$34.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$8.80
$1.36
52 Week High
$32.71
$4.60

Technical Indicators

Market Signals
Indicator
BBNX
CCCC
Relative Strength Index (RSI) 71.48 54.33
Support Level $9.34 $2.13
Resistance Level $15.53 $3.89
Average True Range (ATR) 0.96 0.38
MACD 0.27 -0.05
Stochastic Oscillator 91.73 31.95

Price Performance

Historical Comparison
BBNX
CCCC

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: